Q. Ryan

FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.

R. Pazdur, R. Justice, R. Sridhara, 2008, The oncologist.

Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products.

Mark S Levenson, M. Reichman, T. MaCurdy, 2015, JAMA.

Disparities in erythropoiesis-stimulating agent use after changes in medicare reimbursement and implementation of a risk evaluation and mitigation strategy

T. MaCurdy, D. Graham, J. Kelman, 2022, Drugs & Therapy Perspectives.

Trends in Erythropoiesis‐stimulating agent use and blood transfusions for chemotherapy‐induced anemia throughout FDA's risk evaluation and mitigation strategy lifecycle

T. MaCurdy, D. Graham, J. Kelman, 2021, Pharmacoepidemiology and drug safety.

Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare.

Mark S Levenson, Kimberly A Smith, A. Thompson, 2016, JAMA internal medicine.

Recommendations for achieving interoperable and shareable medical data in the USA

Joseph M. Tonning, J. Brownstein, A. Szarfman, 2022, Communications Medicine.